Impact of HER2-targeted therapy on overall survival (OS) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC).

被引：0
|
作者：
Berghoff, A.
Bartsch, R.
Bago-Horvath, Z.
Dubsky, P. C.
Rudas, M.
Pluschnig, U.
Wiltschke, C.
Gnant, M.
Steger, G. G.
Zielinski, C.
机构：
[1] Med Univ Vienna, Div Oncol, Dept Med 1, Vienna, Austria
[2] Med Univ Vienna, Div Clin Oncol, Dept Med 1, Vienna, Austria
[3] Med Univ Vienna, Dept Pathol, Vienna, Austria
[4] Med Univ Vienna, Dept Surg, Vienna, Austria
[5] Med Univ Vienna, Vienna, Austria
[6] Med Univ Vienna, Ctr Comprehens Canc, Dept Surg, Vienna, Austria
[7] Med Univ Vienna, Ctr Comprehens Canc, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
572
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Systemic therapy and overall survival (OS) in patients (pts) with brain metastases from HER2-positive (HER2+) metastatic breast cancer (MBC).
    Bartsch, R.
    Berghoff, A.
    Pluschnig, U.
    Bago-Horvath, Z.
    Dubsky, P. C.
    Rottenfusser, A.
    Wenzel, C.
    Rudas, M.
    Fitzal, F.
    Dieckmann, K.
    Gnant, M.
    Zielinski, C.
    Steger, G. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Clinical factors associated with overall survival (OS) for patients with HER2-positive (HER2+) metastatic breast cancer (MBC) treated with HER2-targeting systemic therapy (HER2Tx)
    Gullo, G.
    Walsh, N.
    Zacchia, A.
    Hammond, L.
    Fennelly, D.
    Walshe, J.
    O'Mahony, K.
    Maltese, M.
    Crown, J.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S44 - S44
  • [3] The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
    Diogo Mendes
    Carlos Alves
    Noémia Afonso
    Fátima Cardoso
    José Luís Passos-Coelho
    Luís Costa
    Sofia Andrade
    Francisco Batel-Marques
    Breast Cancer Research, 17
  • [4] The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer - a systematic review
    Mendes, Diogo
    Alves, Carlos
    Afonso, Noemia
    Cardoso, Fatima
    Passos-Coelho, Jose Luis
    Costa, Luis
    Andrade, Sofia
    Batel-Marques, Francisco
    BREAST CANCER RESEARCH, 2015, 17
  • [5] HER2-positive (HER2+) metastatic breast cancer (MBC) presentation and patterns of progression
    Di Cosimo, Serena
    Serpico, Danila
    Porcu, Luca
    Tessari, Anna
    Molino, Leonardo
    Torri, Valter
    de Braud, Filippo
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Novel HER2-targeted therapies for HER2-positive metastatic breast cancer
    Kunte, Siddharth
    Abraham, Jame
    Montero, Alberto J.
    CANCER, 2020, 126 (19) : 4278 - 4288
  • [7] Long term survival of vinorelbine (N) and trastuzumab (H) as first line therapy for HER2-positive metastatic breast cancer patients (HER2+ MBC) (pts).
    Chan, A
    Petruzelka, L
    Untch, M
    Martin, M
    Gil, MG
    Porta, VG
    Wojtukiewicz, MZ
    Stewart, A
    Aubert, D
    Gasmi, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 25S - 25S
  • [8] Clinical predictors of long-term survival in Her2-positive (HER2+) metastatic breast cancer (MBC)
    Murthy, Pooja
    Kidwell, Kelley M.
    Thomas, Dafydd G.
    Griggs, Jennifer J.
    Merajver, Sofia D.
    Schott, Anne F.
    Smerage, Jeffrey B.
    Van Poznak, Catherine H.
    Wicha, Max
    Hayes, Daniel F.
    Henry, N. Lynn
    CANCER RESEARCH, 2015, 75
  • [9] Impact of Her-2-Targeted Therapy on Overall Survival in Patients With Her-2 Positive Metastatic Breast Cancer
    Berghoff, Anna S.
    Bago-Horvath, Zsuzsanna
    Dubsky, Peter
    Rudas, Margaretha
    Pluschnig, Ursula
    Wiltschke, Christoph
    Gnant, Michael
    Steger, Guenther G.
    Zielinski, Christoph C.
    Bartsch, Rupert
    BREAST JOURNAL, 2013, 19 (02): : 149 - 155
  • [10] Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting
    Murthy, Rashmi Krishna
    Varma, Ankur
    Mishra, Priyankana
    Hess, Kenneth R.
    Young, Elliana J.
    Murray, James L.
    Koenig, Kimberly Higginbotham
    Green, Marjorie C.
    Moulder, Stacy L.
    Melhem-Bertrandt, Amal
    Booser, Daniel J.
    Valero, Vicente
    Hortobagyi, Gabriel N.
    Esteva, Francisco J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345